Q1 2019/20
Interim financial report, Q1 2019/20
(
Coloplast delivered 8% organic growth in the first quarter. Reported revenue in DKK was up by 9% toDKK 4,712m .- Organic growth rates by business area: Ostomy Care 9%, Continence Care 6%, Interventional Urology 9% and Wound &
Skin Care 10%. - Chronic Care delivered a solid performance in the first quarter, driven by satisfactory momentum in
Europe despite the negative impact from the French price reform and a solid quarter for Emerging markets. - In the US Ostomy business,
Coloplast has been awarded a three-year group purchasing agreement for ostomy products with Premier Inc beginningApril 1, 2020 . - Solid momentum in Emerging markets with 16% organic growth in the first quarter, driven in particular by Ostomy Care and strong performance in
China ,Latin America and timing of tenders inRussia . - The Wound and
Skin Care business delivered 10% organic growth in the first quarter. Wound Care delivered 8% organic growth driven by the Biatain® Silicone portfolio inEurope andSkin Care delivered a solid start to the year. - The Interventional Urology business delivered 9% organic growth, driven by the Men’s Health and Women’s Health portfolios in the US.
- Incremental investments of up to 2% of revenue were made in the first quarter into sales and marketing initiatives across multiple markets and business areas.
- EBIT amounted to
DKK 1,472m for Q1, a 13% increase, corresponding to an EBIT margin of 31% against 30% last year. The comparative period included restructuring costs ofDKK 17m . - ROIC after tax before special items was 47% for Q1 against 44% in the same period last year.
- In Q2 19/20, a new share buyback programme is expected to be launched, totalling
DKK 500m and to be completed by the end of the 2019/20 financial year.
Financial guidance for 2019/20
- We continue to expect organic revenue growth of 7-8% at constant exchange rates and a reported growth in DKK of 7-8%.
- We continue to expect an EBIT margin of ~31% at constant exchange rates and ~31% in DKK. The EBIT margin guidance reflects additional incremental investments of up to 2% of revenue for innovation and sales and marketing initiatives.
Coloplast is monitoring the Coronavirus outbreak inChina closely. The financial impact of the situation is uncertain. Our full year guidance assumes that the situation normalises during Q2.- Capital expenditure is still expected to be DKK ~850m.
- The effective tax rate is still expected to be about ~23%.
Conference call A webcast will be posted on www.coloplast.com shortly after the conclusion of the conference call. |
For more information, please contact:
Investors and analysts
Executive Vice President, CFO
Tel. +45 4911 1111
Ellen Bjurgert
Vice President
Investor Relations
Tel. +45 4911 1800 / 4911 3376
E-mail dkebj@coloplast.com
Senior Manager
Investor Relations
Tel. +45 4911 1800 / 4911 1786
E-mail dkraso@coloplast.com
Press and the media
Director
Corporate Communications
Tel. +45 4911 2608
E-mail dkdk@coloplast.com
Lina Danstrup
Senior Media Relations Manager
Corporate Communications
Tel. +45 4911 2607
E-mail dklina@coloplast.com
Address
Holtedam 1
DK-3050 Humlebaek
Business reg. (CVR) no. 69749917
Website
www.coloplast.com
Attachment
- 01_2020_Q1_201920_earnings_release
© OMX, source